Research New
Merck signs a research deal with Isomorphic Labs to design small-molecule cancer drug candidates with AI
Published:
Merck, known as MSD outside the US and Canada, and Isomorphic Labs, the London-based AI drug-design company led by Demis Hassabis, announced a research collaboration to find small-molecule candidates against an oncology target that neither company named.
Isomorphic will make in silico predictions and deliver molecular designs with its drug design engine, IsoDDE, using proprietary data sets supplied by Merck. Merck takes on preclinical and clinical development, manufacturing and sales. Isomorphic receives an undisclosed upfront payment, milestone payments and tiered royalties, with an option to co-fund development for higher royalties.
Merck's head of discovery George Addona told STAT that the target is one where Merck has already run its own programmes. The deal comes days after Isomorphic's 5 billion dollar Series C, which this paper reported on 17 November.
Caveat. No financial terms or target were disclosed, and AI-designed candidates still face years of preclinical and clinical testing.
Sources